PAX Global 327.HK BUY Dennis Chien
Transcription
PAX Global 327.HK BUY Dennis Chien
[Table_MainInfo] Equity Research Report 24 Oct 2014 [Table_Author] Research Analyst [Table_Title] PAX Global 327.HK Dennis Chien 852 3983 0835 [email protected] [Table_Target] Rating Target Price Upside Potential Company Data (as of 24 Oct mkt close) 327HK Share Price (HK$) Market Cap Outstanding Shares (HK$ mn) (mn) 52wk Low (HK$) 52wk High (HK$) P/E (x) P/B (x) 3.45 EV/EBITDA (x) 11.16 Div yld (%) - ROE (%) 15.74 Net Debt / Equity (%) Net Cash Gearing (%) Auditor Fidelity Share Price Chart (HKD) Expansion in overseas markets faster-than-expected. PAX has [Table_Summary] continually made breakthrough in overseas market for the past few months including partnering with Derpos to expand Turkey market, cooperate with Egyptian govt., joins hands with three big Indonesian banks, being selected by ASB Bank in New Zealand, etc. We expect substitution effects continues at a faster pace where PAX will be able to gain larger market share against peers. The U.S. law shifts the frauds liability from banks to merchants commencing in Oct 2015. PAX has double its team size in the U.S. operations to 35 people, mainly focus on I.T. engineers and salesmen. We expect such action is due to the opportunity rise from EMV migration, weaken competitiveness of competitors, and a more profitable market with aggregate demand of around 2mil ETF-POS terminals each year. According to Payments Security Task Force, a cross-industry group formed by Visa and MasterCard, expected that at least 47% of merchant terminals will be enabled for EMV chip technology by end of 2015 in the U.S. We believe the behind reason is mainly due to change of the U.S. law commencing in Oct 2015, where the liability of any frauds will shift from banks to merchants. Replacement cycle in the U.S. is on-going while potentially there are another 53% of merchant terminals that needed to be replaced after 2015. We expect PAX’s operations in the U.S. will form a larger scale and heading toward breakeven in the coming year. Maintain our Buy rating with target price of HK$9.22. We revise up our FY14E/15E/16E net profit by 16.0%/18.6%/21.2% to HK$382mn/ 477mn/ 597mn. PAX is trading at 17.2x FY15E PER, 35.3% lower than its peer average. We believe the valuation discount will be narrowed given by continuous growth in global market share and weaken competitiveness of competitors. We revise up our target price of HK$9.22, based on 21.3x FY15E PER, a 20% discount from peers average. 7.36 8,098 1,100 2.71 8.49 23.18 PwC Major Shareholders HiSun Technology (maintained) Expect Faster Growth in Overseas Markets Buy (maintained) HK$N/A 9.22 (from HK$8.89) +25.3% Ticker BUY 33.08% 9.04% Forecast and Valuation Year to 31 Dec Revenue (HK$ mn) YoY Net Profit (HK$ mn) YoY Basic EPS (HK$) YoY P/E (x) Dividend yield (%) P/B (x) FY2012 1,313 19.0% 183 0.6% 0.176 0.7% 39.1 4.2 FY2013 FY2014E FY2015E FY2016E 1,472 2,034 2,505 2,926 12.1% 38.1% 23.2% 16.8% 227 382 477 597 23.8% 68.5% 24.9% 25.3% 0.218 0.347 0.433 0.543 23.7% 59.1% 24.9% 25.3% 32.7 22.3 18.1 14.9 3.6 3.3 2.8 2.3 Source: Bloomberg, CIS(HK) estimate Sources: Bloomberg, CIS(HK) Please read the analysts and company disclosure and the disclaimer in the last page Equity Research Report Financial Summary Income Statement (HK$ mn) Total Revenue China market Overseas market Cost of sales Gross profit Other income Operating expense Operating Profit Associates Finance costs Income tax expense Minority interest Others Net Profit EPS No. of shares outstanding (mn) Growth y-o-y Revenue Net Profit EPS FY2012 1,313 919 394 (849) 464 30 (271) 223 (40) 183 0.176 1,038 FY2013 1,472 1,046 426 (931) 541 50 (325) 266 (40) 227 0.218 1,039 FY2014E 2,034 1,224 810 (1,273) 761 58 (372) 446 (65) 382 0.347 1,100 FY2015E 2,505 1,371 1,134 (1,542) 963 70 (476) 557 (81) 477 0.433 1,100 FY2016E 2,926 1,508 1,418 (1,770) 1,156 88 (545) 699 (101) 597 0.543 1,100 19.0% 0.6% 0.52% 12.1% 23.8% 23.65% 38.1% 68.5% 59.14% 23.2% 24.9% 24.86% 16.8% 25.3% 25.34% Balance Sheet (HK$ mn) PPE Others Total Non-Current Assets Inventories Trade and bills receivables Deposits and other receivables Cash at bank and on hand Others Total Current Assets Trade payables Other payables and accruals Borrowings Others Total Current Liabilities Non-current liabilities Total Non-Current Liabilities Share capital Total reserve Total equity Net Cash FY2012 10 0 10 244 544 10 1,358 26 2,183 225 131 0 27 383 0 0 104 1,707 1,811 976 FY2013 8 0 8 465 638 6 1,698 17 2,824 446 275 0 25 746 0 0 104 1,983 2,087 953 FY2014E 12 0 12 488 883 9 1,826 116 3,322 518 320 0 29 866 0 0 110 2,353 2,464 960 FY2015E 13 0 14 558 1,053 10 2,204 117 3,942 609 376 0 52 1,036 0 0 110 2,812 2,922 1,168 FY2016E 16 0 16 679 1,254 12 2,619 116 4,680 690 426 0 63 1,178 0 0 110 3,406 3,516 1,440 Cash Flow (HK$ mn) FY2012 Profit before tax 223 Interest income (11) Depreciation of PPE 3 Others (20) Changes in working capital (2) Income tax paid (29) Net operating cash flows 202 Purchase of PPE (3) Investment in ST bank deposits Interest received 12 Net investing cash flows 1 Proceeds from issuance of ordinary sharesRepayment of ST bank borrowings Increase in restricted cash Net financing activities cash flows 0 Net (decrease) / increase in cash 203 Exchange gains/(losses) 3 Cash at beginning of year 1,152 Cash at end of year 1,358 FY2013 FY2014E FY2015E FY2016E 266 446 557 699 (15) (18) (23) (27) 4 3 3 3 (28) (34) (3) (3) 54 (162) (88) (189) (42) (40) (65) (81) 292 260 385 405 (1) (7) (4) (6) (100) 15 18 23 27 23 (89) 18 22 8 0 0 0 323 171 403 426 17 (44) (25) (12) 1,358 1,698 1,826 2,204 1,698 1,826 2,204 2,619 Ratio Analysis Profitability GPM OPM NPM ROA ROE Liquidity & Solvency Current Ratio Quick Ratio Cash Ratio Total debt to equity Net debt to equity Working Capital AR days Inventories days AP days DuPont Analysis Net Profit Margin Asset Turnover Leverage Ratio FY2013 FY2014E FY2015E FY2016E FY2012 35.3% 17.0% 13.9% 8.3% 10.1% 36.7% 18.1% 15.4% 8.0% 10.9% 37.4% 22.0% 18.8% 11.4% 15.5% 38.5% 22.3% 19.0% 12.0% 16.3% 39.5% 23.9% 20.4% 12.7% 17.0% 5.7 3.8 3.8 3.8 4.0 5.0 3.1 3.3 3.2 3.4 3.5 2.3 2.2 2.2 2.3 0.0% 0.0% 0.0% 0.0% 0.0% Net Cash Net Cash Net Cash Net Cash Net Cash 149 118 160 149 139 211 138 137 223 142 124 216 145 127 216 13.9% 0.6 1.2 15.4% 0.5 1.4 18.8% 0.6 1.4 19.0% 0.6 1.4 20.4% 0.6 1.3 Source: Bloomberg, CIS(HK) Valuation of Peers Name Ticker INGENICO VERIFONE FUJIAN NEWLAND SZZT SHENZHEN XINGUODU ING FP PAY US 000997 CH 002197 CH 300130 CH PAX GLOBAL 327 HK Mkt Cap HK$ mn 43,220 29,866 15,306 5,165 4,556 8,098 Last Px (Local Cur) 78.58 34.05 23.65 15.59 31.43 Simple Avg. 7.36 Current 28.7 N/A 45.4 61.6 59.0 48.7 23.2 P/E ratio FY2014E 23.8 22.9 37.2 41.0 78.6 40.7 21.4 FY2015E 19.5 17.2 27.2 30.4 38.8 26.6 17.2 P/B ratio (x) 5.1 3.6 7.1 3.8 3.3 4.6 3.5 ROA (x) 6.3 (9.1) 6.6 4.0 4.4 2.4 9.0 ROE (x) 18.6 (24.4) 14.3 6.8 5.4 4.1 11.6 Gearing (x) 2.7 2.6 2.2 1.6 1.2 2.0 1.3 Source: Bloomberg, CIS(HK) estimate Please read the analysts and company disclosure and the disclaimer in the last page 2/3 Equity Research Report Disclaimer The information, tools and material presented herein are provided for informational purposes only and are not to be used or considered as an offer or a solicitation to sell or an offer or solicitation to buy or subscribe for securities, investment products or other financial instruments, nor to constitute any advice or recommendation with respect to such securities, investment products or other financial instruments. This research report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. You should independently evaluate particular investments and you should consult an independent financial adviser before making any investments or entering into any transaction in relation to any securities mentioned in this report. The information, tools and material presented herein are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation or which would subject China Investment Securities International Brokerage Limited and China Investment Securities International Futures Limited (Collectively “ China Investment Securities (HK)) to any registration or licensing requirement within such jurisdiction. Information and opinions presented in this report have been obtained or derived from sources believed by China Investment Securities (HK) to be reliable, but China Investment Securities (HK) makes no representation as to their accuracy or completeness and China Investment Securities (HK) accepts no liability for loss arising from the use of the material presented in this report where permitted by law and/or regulation. This report is not to be relied upon in substitution for the exercise of independent judgment. China Investment Securities (HK) may have issued other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them. The research analyst(s) primarily responsible for the preparation of this report confirms that (a) all of the views expressed in this report accurately reflects his or her personal views about any and all of the subject securities or issuers; and (b) that no part of his or her compensation was, is or will be, directly or indirectly, related to the specific recommendations or views he or she expressed in this report. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. China Investment Securities (HK), its directors and employees may have investments in securities or derivatives of any companies mentioned in this report, and may make investment decisions that are inconsistent with the views expressed in this report. General Disclosure China Investment Securities (HK) and its officers, directors and employees, including persons involved in the preparation or issuance of this report, may, to the extent permitted by law, from time to time participate or invest in financing transactions with the issuer(s) of the securities mentioned in this report, perform services for or solicit business from such issuers, and/or have a position or holding, or other material interest, or effect transactions, in such securities or options thereon, or other investments related thereto. In addition, it may make markets in the securities mentioned in the material presented in this report. China Investment Securities (HK) may, to the extent permitted by law, act upon or use the information presented herein, or the research or analysis on which they are based, before the material is published. One or more directors, officers and/or employees of China Investment Securities (HK) may be a director of the issuers of the securities mentioned in this report. This research report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. The information contained herein is believed to be reliable, its completeness and accuracy is however not guaranteed. Opinions expressed in this report are subject to change without notice, and no part of this publication is to be construed as an offer, or solicitation of an offer to buy or sell any securities or financial instruments whether referred therein or otherwise. We do not accept any liability whatsoever whether direct or indirect that may arise from the use of information contained in this report. Regulatory Disclosures as required by the Hong Kong Securities and Futures Commission Policies of China Investment Securities (HK): Research analysts who publish investment research are not directly supervised by, and do not report directly to, investment banking or sales and trading personnel. Research analysts’ compensation or remuneration should not be linked to any specific investment banking function or to recommendations in research. Research analysts or their associates are prohibited from dealing in the securities or any derivatives of any companies the research analysts review/analyse/cover. Research analysts or their associates are prohibited from holding any directorship or other position in any company the research analysts review/analyse/cover. China Investment Securities (HK) is not a market maker in the securities of the subject companies mentioned in this report. China Investment Securities (HK) does not have any investment banking relationship with the companies mentioned in this report within the last 12 months. China Investment Securities (HK) and the research analysts who publish investment research do not have any interests relationship with the companies mentioned above. China Investment Securities International Brokerage Limited 63/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong Tel:(852) 3983 0888 (Office) (852) 3983 0808 (Customer Service) Fax:(852) 3983 0899 (Office) (852) 3983 0855 (Customer Service) http://www.china-invs.hk/ Please read the analysts and company disclosure and the disclaimer in the last page 3/3